Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Enanta Pharmaceuticals (NASDAQ:ENTA) and Eagle Pharmaceuticals Inc (NASDAQ:EGRX).
Enanta Pharmaceuticals (ENTA)
RBC Capital analyst Brian Abrahams reiterated a Hold rating on Enanta Pharmaceuticals today and set a price target of $90. The company’s shares opened today at $88.73.
According to TipRanks.com, Abrahams is a 5-star analyst with an average return of 12.5% and a 55.9% success rate. Abrahams covers the Healthcare sector, focusing on stocks such as Proteostasis Therapeutics Inc, Intra-Cellular Therapies, and Alder Biopharmaceuticals.
Currently, the analyst consensus on Enanta Pharmaceuticals is a Moderate Buy with an average price target of $121.33, a 36.7% upside from current levels. In a report released today, Oppenheimer also downgraded the stock to Hold.
.
See today’s analyst top recommended stocks >>
Eagle Pharmaceuticals Inc (EGRX)
In a report released today, Randall Stanicky from RBC Capital reiterated a Buy rating on Eagle Pharmaceuticals Inc, with a price target of $84. The company’s shares opened today at $78.20.
According to TipRanks.com, Stanicky ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -11.0% and a 33.3% success rate. Stanicky covers the Healthcare sector, focusing on stocks such as Pacira Pharmaceuticals, Evofem Biosciences Inc, and Jazz Pharmaceuticals.
Eagle Pharmaceuticals Inc has an analyst consensus of Strong Buy, with a price target consensus of $76.25, a -2.5% downside from current levels. In a report issued on July 24, Piper Jaffray also reiterated a Buy rating on the stock with a $86 price target.
.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
